Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First battle won with antibodies

08.11.2010
Bacteria that are resistant to antibodies pose a threat, particularly to people who are sick or feeble. In the search for new drugs, scientists from the University of Würzburg have made a breakthrough.

Every year, more than four million patients in Europe develop an infection while staying in hospital – this is because people with ill health are more susceptible than those who are healthy. Responsibility for these so-called hospital infections generally lies with the species of bacteria known as Staphylococcus aureus.


Staphylococcus aureus bacteria (magnification 50,000x). Photo: United States Department of Agriculture

The acronym MRSA has achieved a degree of notoriety in this situation. It denotes strains of the Staphylococcus bacteria that are resistant to the antibiotic methicillin and which are almost impossible to combat using other active agents as well.

Staphylococcus aureus bacteria are also commonly found on the skin of many healthy people where they tend not to cause any problems. But if these pathogens find their way inside the bodies of patients with weakened immune systems, they cause inflammations that are very difficult to cure.

Treatment for resistant bacteria

A promising approach to treating such infections has now been discovered by scientists from the University of Würzburg together with colleagues from the Helmholtz Center for Infection Research in Braunschweig. It is covered in the current issue of the journal Antimicrobial Agents and Chemotherapy.

“We have succeeded in activating a defense mechanism against Staphylococcus pathogens in mice with the help of antibodies,” says Dr. Udo Lorenz from the university’s Department of Surgery I. Together with outside lecturer Dr. Knut Ohlsen from the Institute for Molecular Infection Biology, he has spent the last few years pursuing the idea of combating antibiotic-resistant bacteria with antibodies.

How antibodies work

The principle behind them: certain proteins, known as antibodies, are capable of attaching themselves to a very specific point on the surface of the bacterium. Once there, they can have the following different effects: no effect at all, as the worst-case scenario; as a better scenario, they neutralize the bacterium, preventing it from becoming active again; and, in the ideal scenario, they cause the body’s own immune system to destroy the bacteria.

Activating the immune effector cells: Lorenz and Ohlsen have now managed to do this in mice using an antibody that they themselves have developed. “We were able to show that the rate of bacteria destruction increased by 30 percent after the antibody was administered,” says Lorenz. 30 percent: a "truly dramatic advantage that could mean the difference between death and survival,” explains the medic.

The step from mouse to man

As the next step in their work, the researchers now want to transfer the antibody from mice to people. To ensure that there will be no undesirable rejection reactions, the entire molecule will need to be “humanized”. “We will take only the part of the antibody that docks to the bacterium and will build the rest of the molecule artificially so that it is suitable for people,” says Lorenz.

Once that has been done, the two scientists intend to make a start on the corresponding studies as soon as possible. If everything goes according to plan, Lorenz expects the first clinical study to take place at the end of 2012.

Plan to found a company

For their research into new immunotherapy to treat hospital infections involving resistant Staphylococcus aureus bacteria, Lorenz and Ohlsen are planning to found their own company shortly, which will be called: SmartmAb

SmartmAb will be given the task of developing the mouse antibody for use in people to the point where it is ready for its first clinical trial as a drug. The scientists will then seek to work with a partner from the pharmaceuticals industry on the steps that follow until the drug is ready for the market. The long-term goal is to establish a company that will seek to develop other immunotherapeutics to combat infectious agents based on the first antibodies.

The company’s founders will be receiving financial support from the Federal Ministry of Education and Research. They managed to beat 54 other applicants in the GO-Bio competition and will now be given around three million euros to progress their idea and create a marketable product.

“Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy”. Udo Lorenz, Birgit Lorenz, Tim Schmitter, Karin Streker, Christian Erck, Jürgen Wehland, Joachim Nickel, Bastian Zimmermann and Knut Ohlsen. Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01144-10

Contact

Dr. Udo Lorenz, T +49 (0)931 201 38314, u.lorenz@mail.uni-wuerzburg.de
Dr. Knut Ohlsen, T +49 (0)931 31-82155, knut.ohlsen@mail.uni-wuerzburg.de

Robert Emmerich | Uni Würzburg
Further information:
http://www.uni-wuerzburg.de

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>